ENTO

0.49

3.73% -0.019

Dopo l'orario di chiusura: .43 -0.06 -12.24%

Entero Therapeutics Inc (ENTO)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$0.509

Aprire:

$0.43

Volume 24 ore:

541.22K

Relative Volume:

0.93

Capitalizzazione di mercato:

$2.42M

Reddito:

Utile/perdita netta:

Rapporto P/E:

EPS:

Flusso di cassa netto:

1 W Prestazione:

+2.06%

1M Prestazione:

-11.01%

6M Prestazione:

-5.75%

1 anno Prestazione:

+0.00%

Intervallo 1D:

$0.422

$0.49

Intervallo di 1 settimana:

$0.37

$0.55

Portata 52W:

$0.185

$3.00

Entero Therapeutics Inc Stock (ENTO) Company Profile

Nome

Entero Therapeutics Inc

Settore

Healthcare (1188)

Industria

Biotechnology (681)

Telefono

561-589-7020

Indirizzo

777 YAMATO ROAD, BOCA RATON

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-11

Ultimi documenti SEC

ENTO's Discussions on Twitter

Confronta ENTO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ENTO Entero Therapeutics Inc	0.49	2.42M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	474.56	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	572.78	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	550.00	33.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.95	30.15B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	220.54	25.69B	3.81B	-644.79M	-669.77M	-6.24

Entero Therapeutics Inc Borsa (ENTO) Ultime notizie

Apr 04, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Apr 04, 2025

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 04, 2025

Apr 03, 2025

Entero Therapeutics Enters Rescission Deal to Unwind Merger With ImmunogenX - MarketScreener

Mar 25, 2025

Entero Therapeutics slips 7%, signs rescission agreement with ImmunogenX - MSN

Mar 25, 2025

Mar 24, 2025

Strategic Shift: Entero Therapeutics Unwinds Recent Merger and Strengthens Leadership - Stock Titan

Mar 24, 2025

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC - Yahoo Finance

Mar 24, 2025

Mar 21, 2025

Micron (MU) Stock Trades Down, Here Is Why - The Globe and Mail

Mar 21, 2025

Johnson & Johnson plans $55 billion in US investments over the next four years - The Globe and Mail

Mar 21, 2025

Hogs Close with Weakness on Thursday - The Globe and Mail

Mar 21, 2025

Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace

Mar 21, 2025

Mar 20, 2025

With outlook uncertain, the Bank of England joins the US Fed in putting interest rates on hold - The Globe and Mail

Mar 20, 2025

This Under-the-Radar AI Stock Could Be 1 of the Best Buys for a Recession - The Globe and Mail

Mar 20, 2025

Mar 19, 2025

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Globe and Mail

Mar 19, 2025

Mar 18, 2025

European ETFs Gain Momentum as Global Markets Shift - The Globe and Mail

Mar 18, 2025

The Unpleasant Truth: The Stock Market Is Still Historically Pricey, Even With the Nasdaq and S&P 500 Recently Falling Into Correction Territory - The Globe and Mail

Mar 18, 2025

Mar 17, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Mar 17, 2025

Celiac Disease Market Expected to Experience Major Growth - openPR

Mar 17, 2025

Significant Contract News Sends Energy Services Company Higher - The Globe and Mail

Mar 17, 2025

How Nvidia (NASDAQ:NVDA) Stayed One Step Ahead in the AI Race - The Globe and Mail

Mar 17, 2025

Super Micro's International Presence Makes It a Winning Stock - The Globe and Mail

Mar 17, 2025

Vicarious Surgical Names Sarah Romano as Finance Chief - MPO-mag

Mar 17, 2025

Mar 15, 2025

3 Artificial Intelligence (AI) Stocks That Can Weather President Trump's Tariff Storm - The Globe and Mail

Mar 15, 2025

Mar 14, 2025

Vicarious Surgical appoints Sarah Romano as CFO - MedTech Dive

Mar 14, 2025

Can Nvidia’s Stock Keep Climbing as Foxconn Bets Big on AI? - The Globe and Mail

Mar 14, 2025

Greif Named 2025 Gallup Exceptional Workplace Award Winner - The Globe and Mail

Mar 14, 2025

Mar 13, 2025

Vicarious Surgical names Sarah Romano as new CFO By Investing.com - Investing.com Australia

Mar 13, 2025

Vicarious Surgical Appoints Sarah Romano as Chief Financial Officer - citybiz

Mar 13, 2025

Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer - Business Wire

Mar 13, 2025

Mar 12, 2025

3 Ways Tech Investors Can Navigate the Artificial Intelligence (AI) Sector Tumble - The Globe and Mail

Mar 12, 2025

Mar 11, 2025

Stocks Mixed as President Trump Ramps Up Tariffs on Canada - The Globe and Mail

Mar 11, 2025

Mar 10, 2025

Goldman Sachs: Buy These 2 ‘Rising Star’ Stocks in 2025 - The Globe and Mail

Mar 10, 2025

Mar 05, 2025

Where Will Coca-Cola Stock Be in 5 Years? - The Globe and Mail

Mar 05, 2025

Mar 04, 2025

Reflecting On Auto Parts Retailer Stocks’ Q4 Earnings: AutoZone (NYSE:AZO) - The Globe and Mail

Mar 04, 2025

Mar 03, 2025

Onconetix taps industry veteran as executive chairman amid CEO resignationCincinnati Business Courier - Cincinnati Business Courier

Mar 03, 2025

Feb 28, 2025

Onconetix names new executive chairman, appoints board member - Investing.com

Feb 28, 2025

Feb 26, 2025

iHeartMedia (IHRT) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail

Feb 26, 2025

Feb 17, 2025

Entero Therapeutics Appoints Richard Paolone as CEO - citybiz

Feb 17, 2025

Feb 16, 2025

AzurRx BioPharma Receives Approximately $550,000 for its 2020 CIR (French Research Tax Credit) - Marketscreener.com

Feb 16, 2025

Feb 15, 2025

Entero Therapeutics names Richard Paolone interim CEO - MSN

Feb 15, 2025

Feb 14, 2025

Entero Therapeutics Appoints Richard Paolone as Interim CEO - TipRanks

Feb 14, 2025

Entero Therapeutics names Richard Paolone interim CEO By Investing.com - Investing.com South Africa

Feb 14, 2025

Entero Therapeutics Names Richard Paolone Interim CEO - MarketWatch

Feb 14, 2025

Entero Therapeutics Names Richard Paolone Interim CEO -February 14, 2025 at 04:25 pm EST - Marketscreener.com

Feb 14, 2025

Strategic Leadership Shift: M&A Expert Takes Helm at Entero TherapeuticsKey Details Revealed - StockTitan

Feb 14, 2025

Feb 11, 2025

Entero Therapeutics, Inc. announced that it has received $2 million in funding from 1396974 B.C. Ltd - Marketscreener.com

Feb 11, 2025

Feb 10, 2025